PTCT vs. INDV, ACAD, DYN, RYTM, JANX, VERA, GERN, MLTX, BHC, and ARVN
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Indivior (INDV), ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Rhythm Pharmaceuticals (RYTM), Janux Therapeutics (JANX), Vera Therapeutics (VERA), Geron (GERN), MoonLake Immunotherapeutics (MLTX), Bausch Health Companies (BHC), and Arvinas (ARVN). These companies are all part of the "pharmaceutical preparations" industry.
PTC Therapeutics (NASDAQ:PTCT) and Indivior (NASDAQ:INDV) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.
PTC Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
PTC Therapeutics received 537 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 62.03% of users gave PTC Therapeutics an outperform vote.
PTC Therapeutics presently has a consensus price target of $33.67, indicating a potential upside of 1.73%. Indivior has a consensus price target of $36.00, indicating a potential upside of 112.14%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than PTC Therapeutics.
Indivior has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Indivior has a net margin of 0.44% compared to PTC Therapeutics' net margin of -62.45%. Indivior's return on equity of 842.72% beat PTC Therapeutics' return on equity.
In the previous week, PTC Therapeutics had 4 more articles in the media than Indivior. MarketBeat recorded 4 mentions for PTC Therapeutics and 0 mentions for Indivior. PTC Therapeutics' average media sentiment score of 0.85 beat Indivior's score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the media.
60.3% of Indivior shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Indivior beats PTC Therapeutics on 11 of the 17 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
